Peter Radovich - 15 Mar 2026 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: PRESIDENT AND COO
Issuer ticker: MIRM
Reported as of: 15 Mar 2026
Net transaction value: -$1,519,015
SEC form: 4
Accepted by SEC: 17 Mar 2026, 19:30:16 UTC
Prior SEC filing: 11 Mar 2026
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Peter Radovich filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 17 Mar 2026.

Key facts

This page summarizes Peter Radovich's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 19:30.

Change

Previous filing in this sequence was filed on 11 Mar 2026.
Current net transaction value: -$1,519,015.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001650131 Primary reporting owner

Radovich Peter

Relationship: PRESIDENT AND COO
Address: C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY
Signature: /s/ Judit Ryvkin, Attorney-in-Fact
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,220
Change %: +27%
Price
Shares after: 33,787
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

MIRM transaction

Common Stock

Options Exercise

Transaction value
Shares: +23,000
Change %: +68%
Price
Shares after: 56,787
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

MIRM transaction

Common Stock

Sale

Transaction value: $1,519,015
Shares: -16,515
Change %: -29%
Price: $91.98
Shares after: 40,272
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRM transaction Derivative

Performance Restricted Stock Units

Options Exercise

Transaction value
Shares: -7,220
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,220
Exercise price
Footnotes: F1, F3

MIRM transaction Derivative

Performance Restricted Stock Units

Options Exercise

Transaction value
Shares: -23,000
Change %: -67%
Price: $0.000000^*
Shares after: 11,500
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,000
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.

Footnote F3

The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.

Footnote F4

The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.